These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 24461738

  • 1. [New therapies for rheumatoid arthritis].
    Salgado E, Maneiro JR.
    Med Clin (Barc); 2014 Nov 18; 143(10):461-6. PubMed ID: 24461738
    [Abstract] [Full Text] [Related]

  • 2. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH, Bae SC.
    Int J Rheum Dis; 2016 Nov 18; 19(11):1103-1111. PubMed ID: 26692536
    [Abstract] [Full Text] [Related]

  • 3. Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.
    Vieira MC, Zwillich SH, Jansen JP, Smiechowski B, Spurden D, Wallenstein GV.
    Clin Ther; 2016 Dec 18; 38(12):2628-2641.e5. PubMed ID: 27889300
    [Abstract] [Full Text] [Related]

  • 4. Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments.
    Xie F, Yun H, Bernatsky S, Curtis JR.
    Arthritis Rheumatol; 2016 Nov 18; 68(11):2612-2617. PubMed ID: 27213279
    [Abstract] [Full Text] [Related]

  • 5. Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice: A Nationwide Cohort Study From Sweden.
    Wadström H, Frisell T, Askling J, Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group.
    JAMA Intern Med; 2017 Nov 01; 177(11):1605-1612. PubMed ID: 28975211
    [Abstract] [Full Text] [Related]

  • 6. Rheumatoid arthritis: Biological therapy other than anti-TNF.
    Rossi D, Modena V, Sciascia S, Roccatello D.
    Int Immunopharmacol; 2015 Aug 01; 27(2):185-8. PubMed ID: 25840282
    [Abstract] [Full Text] [Related]

  • 7. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ, Hyrich KL.
    BioDrugs; 2009 Aug 01; 23(2):111-24. PubMed ID: 19489652
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
    Isaacs JD.
    Expert Opin Biol Ther; 2009 Dec 01; 9(12):1463-75. PubMed ID: 19916731
    [Abstract] [Full Text] [Related]

  • 9. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
    Prescrire Int; 2010 Feb 01; 19(105):30-4. PubMed ID: 20455343
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis.
    Iannone F, Lopalco G, Cantarini L, Galeazzi M, Lapadula G.
    Clin Rheumatol; 2016 Jan 01; 35(1):19-23. PubMed ID: 26581205
    [Abstract] [Full Text] [Related]

  • 11. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
    Tanaka Y, Yamaoka K.
    Mod Rheumatol; 2013 May 01; 23(3):415-24. PubMed ID: 23212593
    [Abstract] [Full Text] [Related]

  • 12. New therapies for treatment of rheumatoid arthritis.
    Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P.
    Lancet; 2007 Dec 01; 370(9602):1861-74. PubMed ID: 17570481
    [Abstract] [Full Text] [Related]

  • 13. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors].
    Swierkot J, Madej M.
    Pol Merkur Lekarski; 2011 Apr 01; 30(178):289-94. PubMed ID: 21595177
    [Abstract] [Full Text] [Related]

  • 14. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
    Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, Shurmur R, Singhal AK, Wei N, Rosengren S, Kaplan I, Krishnaswami S, Luo Z, Bradley J, Firestein GS.
    Ann Rheum Dis; 2015 Jun 01; 74(6):1311-6. PubMed ID: 25398374
    [Abstract] [Full Text] [Related]

  • 15. Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.
    Tanaka Y.
    J Biochem; 2015 Sep 01; 158(3):173-9. PubMed ID: 26152731
    [Abstract] [Full Text] [Related]

  • 16. Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study.
    Curtis JR, Sarsour K, Napalkov P, Costa LA, Schulman KL.
    Arthritis Res Ther; 2015 Nov 11; 17():319. PubMed ID: 26555431
    [Abstract] [Full Text] [Related]

  • 17. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.
    Woodworth TG, den Broeder AA.
    Best Pract Res Clin Rheumatol; 2015 Nov 11; 29(4-5):543-9. PubMed ID: 26697765
    [Abstract] [Full Text] [Related]

  • 18. Targeted therapy in rheumatoid arthritis.
    Köller MD.
    Wien Med Wochenschr; 2006 Jan 11; 156(1-2):53-60. PubMed ID: 16465614
    [Abstract] [Full Text] [Related]

  • 19. Comparative efficacy of tocilizumab, abatacept and rituximab after non-TNF inhibitor failure: results from a multicentre study.
    Pascart T, Philippe P, Drumez E, Deprez X, Cortet B, Duhamel A, Houvenagel E, Flipo RM.
    Int J Rheum Dis; 2016 Nov 11; 19(11):1093-1102. PubMed ID: 27018857
    [Abstract] [Full Text] [Related]

  • 20. [Indications and efficacy of biologics in inflammatory arthritis].
    Combe B.
    Bull Acad Natl Med; 2012 Oct 11; 196(7):1279-92; discussion 1293. PubMed ID: 23815014
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.